- Home
- SJT vs ARCT Comparison
SJT vs ARCT Comparison
Compare SJT & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJT
- ARCT
- Stock Information
- Founded
- SJT 1980
- ARCT 2013
- Country
- SJT United States
- ARCT United States
- Employees
- SJT N/A
- ARCT N/A
- Industry
- SJT Oil & Gas Production
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- SJT Energy
- ARCT Health Care
- Exchange
- SJT Nasdaq
- ARCT Nasdaq
- Market Cap
- SJT 290.4M
- ARCT 298.3M
- IPO Year
- SJT N/A
- ARCT N/A
- Fundamental
- Price
- SJT $6.34
- ARCT $11.86
- Analyst Decision
- SJT
- ARCT Strong Buy
- Analyst Count
- SJT 0
- ARCT 7
- Target Price
- SJT N/A
- ARCT $57.40
- AVG Volume (30 Days)
- SJT 319.9K
- ARCT 410.5K
- Earning Date
- SJT 05-27-2025
- ARCT 05-12-2025
- Dividend Yield
- SJT N/A
- ARCT N/A
- EPS Growth
- SJT N/A
- ARCT N/A
- EPS
- SJT 0.11
- ARCT N/A
- Revenue
- SJT $7,032,254.00
- ARCT $143,680,000.00
- Revenue This Year
- SJT N/A
- ARCT N/A
- Revenue Next Year
- SJT N/A
- ARCT $44.93
- P/E Ratio
- SJT $57.11
- ARCT N/A
- Revenue Growth
- SJT N/A
- ARCT 15.38
- 52 Week Low
- SJT $3.21
- ARCT $8.04
- 52 Week High
- SJT $6.49
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- SJT 61.85
- ARCT 50.74
- Support Level
- SJT $6.03
- ARCT $10.70
- Resistance Level
- SJT $6.72
- ARCT $13.10
- Average True Range (ATR)
- SJT 0.32
- ARCT 0.89
- MACD
- SJT 0.02
- ARCT -0.01
- Stochastic Oscillator
- SJT 62.00
- ARCT 35.69
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.